BIO

• CAT Number: I004510
• CAS Number: 667463-62-9
• Molecular Formula: C₁₆H₁₀BrN₃O₂
• Molecular Weight: 356.17
• Purity: ≥95%
• Synonyms: 6-bromo-3-[3-(hydroxyamino)indol-2-ylidene]-1H-indol-2-one
• Target: GSK-3
• Solubility: DMSO: ≥ 23 mg/mL
• Storage: 2-8°C
• IC50: 5 nM(GSK-3α/β); 20 nM(CDK1-cyclinB) [1][2]
• IUPAC Name: 6-bromo-3-(3-nitroso-1H-indol-2-yl)-1H-indol-2-ol
• InChI: InChI=1S/C16H10BrN3O2/c17-8-5-6-9-12(7-8)19-16(21)13(9)15-14(20-22)10-3-1-2-4-11(10)18-15/h1-7,18-19,21H
• InChIKey: SAQUSDSPQYQNBG-UHFFFAOYSA-N
• SMILES: C1=CC=C2C(=C1)C(=C(N2)C3=C(NC4=C3C=CC(=C4)Br)O)N=O

BIO (Cat No.:I004510) is a potent, selective inhibitor of glycogen synthase kinase-3 (GSK-3), an enzyme involved in numerous cellular processes, including cell fate, differentiation, and apoptosis. By inhibiting GSK-3, BIO activates Wnt/β-catenin signaling, promoting cell proliferation and stem cell self-renewal. It is widely used in stem cell research to enhance pluripotency and maintain undifferentiated states in embryonic stem cells. BIO is also explored for its neuroprotective effects in neurodegenerative disease models, as GSK-3 inhibition is linked to reduced neuronal damage and enhanced survival. It is a valuable tool for developmental biology and regenerative medicine research.

Reference

[1]. Polychronopoulos P, et al. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J Med Chem. 2004 Feb 12;47(4):935-46.
[2]. Meijer L, et al. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 2004 Sep;25(9):471-80.